MEDI8367 / AstraZeneca - LARVOL DELTA

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed | N=70 ➔ 12

Enrollment change • Trial completion • Chronic Kidney Disease • Nephrology • Renal Disease • CRP • CST3

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease (clinicaltrials.gov) - P1; N=70; Active, not recruiting; Sponsor: AstraZeneca; Trial completion date: Jun 2021 ➔ Apr 2022; Trial primary completion date: Jun 2021 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • Chronic Kidney Disease • Nephrology • Renal Disease • ALB • CRP • CST3

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease (clinicaltrials.gov) - P1; N=70; Active, not recruiting; Sponsor: AstraZeneca; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Chronic Kidney Disease • Nephrology • Renal Disease • CRP • CST3

[VIRTUAL] Targeting αvβ8 Integrin Improves Renal Function Through Local Inhibition of TGF-β Activation (KIDNEY WEEK 2020) - " We generated MEDI8367, an antibody that specifically binds human integrin β8 and works allosterically reducing its affinity for the LAP domain, hence preventing β8-mediated TGFβ activation but not its cell adhesion function... We conclude that targeting integrin β8 in CKD ameliorates kidney dysfunction and reduces fibrosis, an effect that is mediated by inhibition of local TGFβ activation."

Chronic Kidney Disease • Diabetic Nephropathy • Fibrosis • Immunology • Nephrology • Renal Disease

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease (clinicaltrials.gov) - P1; N=70; Recruiting; Sponsor: AstraZeneca; Not yet recruiting ➔ Recruiting; Trial completion date: Sep 2021 ➔ Jun 2021; Trial primary completion date: Sep 2021 ➔ Jun 2021

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Chronic Kidney Disease • Nephrology • Renal Disease • CRP • CST3

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease. (clinicaltrials.gov) - P1; N=70; Not yet recruiting; Sponsor: AstraZeneca

Clinical • New P1 trial • Chronic Kidney Disease • Nephrology • Renal Disease